Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 02

248P - Targeting triple-negative breast cancer metabolism with neoadjuvant chemotherapy plus fasting-mimicking diet plus/minus metformin: The BREAKFAST trial

Date

21 Oct 2023

Session

Poster session 02

Topics

Translational Research

Tumour Site

Breast Cancer

Presenters

Francesca Ligorio

Citation

Annals of Oncology (2023) 34 (suppl_2): S278-S324. 10.1016/S0923-7534(23)01258-9

Authors

F. Ligorio1, G. Fucà1, A. Vingiani2, F. Iannelli3, R. Lobefaro1, C. Ferraris4, A. Belfiore5, G. Scaperrotta6, C. Depretto6, A. Martinetti1, P. Corsetto7, G.V. Bianchi1, G. Capri1, S. Folli4, S. Minucci8, M. Foiani9, M. Pagani10, G. Pruneri2, F.G.M. De Braud1, C. Vernieri1

Author affiliations

  • 1 Medical Oncology And Hematology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Department Of Advanced Diagnostics, Molecular Tumor Board & Department Of Oncology And Hemato-oncology, University Of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 3 Bioinformatics, IFOM ETS-the AIRC Institute of Molecular Oncology, 20139 - Milan/IT
  • 4 Breast Unit, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT
  • 5 Department Of Advanced Diagnostics, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 6 Department Of Radiology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 7 Department Of Pharmacological And Biomolecular Sciences, UNIMI - Università degli Studi di Milano Statale, 20121 - Milan/IT
  • 8 Department Of Experimental Oncology, European Institute of Oncology, 20141 - Milan/IT
  • 9 Genome Integrity Research Lab, IFOM-IEO Campus, 20139 - Milan/IT
  • 10 Molecular Oncology And Immunology, IFOM-IEO Campus, 20139 - Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 248P

Background

Cyclic fasting or fasting-mimicking diets (FMDs) enhanced the antitumor activity of chemotherapy (CT) in TNBC mouse models, while the combination of fasting and metformin resulted in impressive antitumor activity in several preclinical tumor models. The BREAKFAST study was designed to investigate if cyclic FMD, plus/minus metformin, improves the antitumor activity of neoadjuvant CT in patients (pts) with localized TNBC.

Methods

BREAKFAST is a randomized, non-comparative, phase II trial originally designed to enrol 90 stage I-III (cT>1cm) TNBC pts candidate to receive neoadjuvant doxorubicin-cyclophosphamide q3w for 4 cycles, followed by weekly paclitaxel for 12 cycles. Pts were randomized 1:1 to receive: CT + triweekly 5-day FMD cycles (arm A), or CT + FMD + daily metformin (1700 mg) (arm B). The primary study objective was to investigate if one or both experimental treatments were able to increase pCR rates when compared to anthracycline-taxane CT alone according to historical data.

Results

We enrolled 30 pts between June 2020 and February 2022, when the study was prematurely interrupted after the introduction of chemo-immunotherapy (CT-IO) as a standard neoadjuvant therapy for early stage TNBC. Of these pts, 13 were randomized to arm A and 17 to arm B; 73.3% of enrolled pts completed the maximum of 8 FMD cycles, with an average number of 6.9 completed FMD cycles. The observed pCR rate was 56.6%, i.e., significantly higher than pCR rates previously reported with CT alone in phase II/III trials (26-39%), and with no significant differences among treatment arms (OR 1.67, 95% CI 0.39-7.43; p=0.49). RNA-seq analysis in tumor specimens revealed higher pCR probability in pts undergoing precocious enhancement of tumor infiltration by activated T and NK cells, as well as precocious downmodulation of glycolysis and oxidative mitochondrial metabolism pathways.

Conclusions

Preoperative CT plus cyclic FMD (plus/minus metformin) results in excellent pCR rates in early TNBC pts. Based on these findings, we recently initiated a phase II, randomized, multicentric trial, namely BREAKFAST-2, to investigate if adding cyclic FMD to neoadjuvant CT-IO increases pCR rates in stage II-III TNBC pts.

Clinical trial identification

NCT04248998.

Editorial acknowledgement

Legal entity responsible for the study

Fondazione IRCCS Istituto Nazionale dei Tumori.

Funding

Fondazione IRCSS Istituto Nazionale dei Tumori; AIRC.

Disclosure

F. Ligorio: Financial Interests, Personal, Other, Travel/accomodation: Eli Lilly, Istituto Gentili; Financial Interests, Personal, Invited Speaker: Novartis. R. Lobefaro: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: Pfizer; Financial Interests, Personal, Other, Travel/accomodation: Eli Lilly. G.V. Bianchi: Financial Interests, Personal, Advisory Board: Novartis, Eli Lilly, Daiichi Sankyo, AstraZeneca, Roche, MSD, Seagen. G. Pruneri: Financial Interests, Personal, Advisory Role: Roche, Bayer; Financial Interests, Personal, Advisory Board: AstraZeneca. F.G.M. De Braud: Financial Interests, Personal, Advisory Board: Roche, EMD Serono, NMS Nerviano Medica Science, Sanofi, MSD, Novartis, Incyte, BMS, Menarini, AstraZeneca, Pierre Fabre, Mattioli 1885 , MCCann Health, Taiho, IQVIA; Financial Interests, Personal, Speaker’s Bureau: BMS, Healthcare Research & Parmacoepidemiology, Merck Group, MSD, Pfizer, Servier, Sanofi, Roche, AMGEN, Incyte, Dephaforum, Seagen, Nadirex, Ambrosetti, Itanet; Financial Interests, Personal and Institutional, Sponsor/Funding: Novartis, F.Hoffmann-LaRoche Ltd, BMS, Ignyta Operating INC, Merck Sharp & Dohme Spa, Kymab, Pfizer, Tesaro, MSD, MedImmune LCC, Exelixis Inc., LOXO Oncology Incorporated, Daiichi Sankyo, Basilea Pharmaceutica International AG, Janssen-Cilag Internationa NV, Merck KGAA. C. Vernieri: Financial Interests, Personal, Advisory Board: Novartis, Pfizer, Lilly, Daiichi Sankyo, Novartis, Lilly, Istituto Gentili; Financial Interests, Institutional, Research Grant: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.